Study on the value of Foxp3 + Tregs level in peripheral blood of patients with relapsed and refractory acute lymphoblastic leukemia after CAR-T cell therapy
赵静,钱韦韦,曹江,李玉平,谢丽丽,郁子馨
DOI: https://doi.org/10.3760/cma.j.issn.1673-4394.2020.06.010
2020-01-01
International Journal of Immunology
Abstract:Objective:To investigate the relationship between recurrence and the level of Foxp3
+ regulatory T cells (Tregs) in peripheral blood in patients with relapsed refractory acute lymphoblastic leukemia (R/R ALL) after treatment with chimeric antigen receptor T-Cell immunotherapy (CAR-T).
Method:From January 2016 to January 2019, 43 patients with R/R ALL relapsed and refractory acute lymphoblastic leukemia in Affiliated Hospital of Xuzhou Medical University were selected as the study group, and 43 healthy people in the same period were selected as the control group. Fasting peripheral blood samples were taken after admission to the hospital to determine the ratio of T cell, CD4
+ CD25
+ Tregs, CD4
+ CD25
+ Foxp3
+ Tregs using flow cytometry. and CAR-T cell immunotherapy was used.The proportion of T cell, CD4
+ CD25
+ Tregs, CD4
+ CD25
+ Foxp3
+ Tregs in the study group and the control group, patients with different curative effects and different prognostic effects were counted, and the correlation between each index and curative effect and prognosis was analyzed.
Result:The proportion of T cells, CD4
+ CD25
+ Tregs and CD4
+ CD25
+ Foxp3
+ Tregs in the study group were (67.32±13.29)%, (5.40±1.35)%, (4.81±1.28)%, which were significantly higher than those in the control group [(25.81±7.61)%, (3.10±0.66)%, (2.80±0.75)% ](all
P values <0.05). The percentage of T cells, CD4
+ CD25
+ Tregs and CD4
+ CD25
+ Foxp3
+ Tregs in patients with partial remission were (46.18±10.22)%, (4.13±1.12)%, (3.64±0.91)%, respectively, while those without remission were (68.29±14.13)%, (5.51±1.40)%, (4.93±1.32)%, respectively .The proportion of T cell, CD4
+ CD25
+ Tregs and CD4
+ CD25
+ Foxp3
+ Tregs in complete remission group were (30.79±6.53)%, (3.29±0.73)%, and (2.91±0.80)%, respectively, which were lower than those of partial remission (all
P values <0.05) .The cell, CD4
+ CD25
+ Tregs and CD4
+ CD25
+ Foxp3
+ Tregs were (29.79±7.01)%, (3.18±0.75) and (2.86±0.79)%, respectively. The recurrence rates were (66.13±14.06)%, (5.33±1.30)%, (4.77±1.13)%, respectively. The levels of T cells, CD4
+ CD25
+ Tregs and CD4
+ CD25
+ Foxp3
+ Tregs were (29.79±7.01)%, (3.18±0.75)% and (2.86±0.79)%, respectively.T Cells, CD4
+ CD25
+ Tregs, CD4
+ CD25
+ Foxp3
+ Tregs were negatively correlated with clinical efficacy and prognosis (
r=-0.661, -0.791, -0.766, -0.621, -0.761, -0.772, all
P values <0.05).
Conclusion:Foxp3
+ Tregs levels in peripheral blood of patients with relapsed and refractory acute lymphoblastic leukemia R/R ALL were abnormal. There were significant differences in CD4
+ CD25
+ Foxp3
+ Tregs levels in patients with different curative effects and relapse conditions after CAR-T cell immunotherapy, and there was a significant negative correlation between them.